Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213124 | 0.84 | HTR1F (0.56) | HTR1FKMT2APFKFB3HTR6TDP1 | |
| SCHEMBL5208596 | 0.83 | HTR1F (0.53) | HTR1FKMT2ANPSR1EGFRFGFR1 | |
| SCHEMBL5212374 | 0.81 | HTR1F (0.56) | HTR1FPIP5K1CPIK3CAGSK3BDYRK1A | |
| SCHEMBL5212799 | 0.81 | HTR1F (0.61) | HTR1FKMT2ANPSR1 | |
| SCHEMBL5207977 | 0.81 | HTR1F (0.53) | HTR1FKMT2AHTR6NPSR1EGFR | |
| SCHEMBL5215789 | 0.81 | HTR1F (0.53) | HTR1FKMT2AHTR2ANPSR1TDP1 | |
| SCHEMBL5210057 | 0.80 | HTR1F (0.51) | HTR1FKMT2AEGFRFGFR1KDR | |
| SCHEMBL5210116 | 0.80 | HTR1F (0.53) | HTR1FKMT2AHTR6NPSR1EGFR | |
| SCHEMBL5212898 | 0.80 | MEN1 (0.46) | HTR1FKMT2AHTR2AHTR2BHTR6 | |
| SCHEMBL5216545 | 0.80 | HTR1F (0.58) | HTR1FKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153013-B1 | 5-HT1F AGONISTS | LILLY CO ELI (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| US-6777428-B1 | INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | ELI LILLY AND COMPANY | 2004-08-17 | — | — | US | disclosed |
| CN-1149195-C | 5-HTIF agonists | — | 2004-05-12 | — | — | CN | disclosed |
| CN-1340045-A | 5-HTIF agonists | LILLY CO ELI (US) | 2002-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1F 1/4885KMT2A 3859/4885PFKFB3 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.